Table 1.
Accession number, chromosome location and possible role in the pathogenesis of SLE of selected genes whose expression was repressed when untreated patients were compared to healthy individuals, and genes whose expression was induced when untreated patients were compared to treated ones
| (’000 MW) | Accession no. | Location | Associations with SLE pathogenesis | *Fold change | †q-value |
|---|---|---|---|---|---|
| Repressed genes | |||||
| Small nuclear ribonucleoprotein (70) | R02346 | 19q13.3 | SLE autoantigen | −7·812 | 23·91 |
| Splicing factor 3a, subunit 3 (60) | R43015 | 1p34.2 | SLE autoantigen | −2·153 | 23·91 |
| Nucleolar autoantigen (55) | W81191 | 17q21.2 | Autoantigen, interstitial cystitis | −3·175 | 23·91 |
| Tetranectin (plasminogen-binding protein) | W73889 | 3p21 | Plasminogen activation | −1·748 | 23·91 |
| TNF (ligand), member 9 | AA778663 | 19p13.3 | SLE nephritis development | −3·958 | 23·91 |
| CD22 antigen | N53534 | 19q13.1 | B-cell receptor regulation | −2·387 | 30·26 |
| Zinc finger protein 74 | AA629838 | 22q11.21 | Not yet associated to SLE | −3·149 | 23·91 |
| Phosphonoformate immuno-associated protein 5 | W80632 | 13 | Not yet associated to SLE | −1·912 | 30·26 |
| E1b (55) associated protein 5 | AA464198 | 19q13.13 | Not yet associated to SLE | −1·807 | 23·91 |
| Sema domain, Ig domain | AA454570 | 3p21.3 | Not yet associated to SLE | −8·387 | 23·91 |
| Induced genes | |||||
| Fc fragment of IgG, receptor for CD32 | R68106 | 1q23 | Antibody modulation | 7·876 | 38·31 |
| Apoptotic protease activating factor | N51014 | 12q21 | Apoptosis | 2·437 | 38·31 |
| Cytochrome-c oxidase subunity VIc | AA456931 | 8q22 | Apoptosis | 3·318 | 38·31 |
| Cytochrome-c oxidase subunity VIII | AA862813 | 11q13 | Apoptosis | 1·921 | 38·31 |
| Complement component 5 (C5) | N53664 | 9q32 | Complement system pathway | 2·591 | 38·31 |
| MHC, class II, DR α (HLA-DRA) | R47979 | 6p21.3 | Susceptibility to SLE | 148·387 | 38·31 |
| MHC, class II, DP β 1 (HLA-DPB1) | AA486532 | 6p21.3 | Susceptibility to SLE | 19·630 | 38·31 |
| TGF-β R II | AA487034 | 3p22 | Cell growth and differentiation | 62·562 | 38·31 |
| Thyroid autoantigen (70) (Ku antigen) | AA486207 | 22q13 | SLE autoantigen | 2·842 | 38·31 |
| Small nuclear ribonucleoprotein (SNRPN) | T54926 | 15q12 | SLE autoantigen | 3·369 | 38·31 |
| Heterogeneous nuclear RNP-C (HRNPC) | H05899 | 14q11.1 | mRNA processing and splicing | 1·523 | 38·31 |
| Splicing factor arg/ser rich 9 (SFRS9) | AA491213 | 12q24.31 | mRNA processing and splicing | 1·623 | 38·31 |
| Argininosuccinate lyase (ASL) | AA486741 | 7cen-q11.2 | NO production | 5·056 | 38·31 |
| Tumour protein p53 (TP53) | R39356 | 17p13.1 | Tumour suppressor | 4·676 | 38·31 |
| Mannosidase-α, class 1A, member 1 | T91261 | 6p22 | Mannose removal | 10·825 | 38·31 |
| TNF (ligand), member 9 | AA778663 | 19p13.3 | SLE nephritis development | 3·512 | 38·31 |
| CD22 antigen | N53534 | 19q13.1 | B-cell receptor regulation | 91·725 | 38·31 |
| Zinc finger protein 74 | AA629838 | 22q11.21 | Not yet associated to SLE | 3·872 | 38·31 |
| Phosphonoformate immuno-associated protein 5 | W80632 | 13 | Not yet associated to SLE | 2·878 | 38·31 |
| Elb (55) associated protein 5 | AA464198 | 19q13.13 | Not yet associated to SLE | 1·366 | 38·31 |
| Sema domain, Ig domain | AA454570 | 3p21.3 | Not yet associated to SLE | 8·764 | 38·31 |
*
Fold change is the variability in the gene expression between patient and normal individuals or treated and untreated patients (negative values correspond to repressed and positive values to induced genes).
†
q-value is a P-value adapted for multiple testing to measure the difference in the expression of each gene.
Ig, immunoglobulin; TNF, tumour necrosis factor.